We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Minerva Neurosciences Inc (NERV) USD0.0001

Sell:$0.37 Buy:$0.40 Change: $0.0092 (2.42%)
Market closed |  Prices as at close on 16 May 2022 | Switch to live prices |
Change: $0.0092 (2.42%)
Market closed |  Prices as at close on 16 May 2022 | Switch to live prices |
Change: $0.0092 (2.42%)
Market closed |  Prices as at close on 16 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's lead product candidates are roluperidone (MIN-101), seltorexant and MIN-301. Roluperidone (MIN-101) is a compound that blocks serotonin, sigma, and α adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. The Company is developing roluperidone to treat patients with schizophrenia. Roluperidone is designed to block a specific subtype of serotonin receptor called 5-HT2A. The Company is developing seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson’s disease and for other neurodegenerative disorders.

Contact details

1601 Trapelo Rd Ste 286
United States
+1 (617) 6007373

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$16.45 million
Shares in issue:
42.72 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Remy Luthringer
    Executive Chairman of the Board of Directors, Chief Executive Officer
  • Geoffrey Race
  • Frederick Ahlholm
    Chief Financial Officer, Senior Vice President - Finance
  • Joseph Reilly
    Chief Operating Officer, Senior Vice President
  • Devin Smith
    Senior Vice President, General Counsel
  • Ramana Kuchibhatla
    Senior Vice President - Head of Research & Development
  • Michael Davidson
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.